jump to navigation

Ovarian cancer forms outside ovaries March 3, 2012

Posted by patoconnor in cancer, gynecological cancer, ovarian cancer, tubal cancer, Uncategorized, uterine cancer, vaginal cancer.
Tags: , , , ,
add a comment

Ovarian cancer forms outside ovaries

Sat Mar 3, 2012

In a startling revelation, a new study has found that the deadliest type of ovarian cancer, high grade serous cancer (HGSC), which accounts for 90 per cent of deaths, often starts in the fallopian tubes rather than the ovaries. If the symptoms are recognised early enough, it can be diagnosed and treated effectively, say the findings of the DOvE (Diagnosing Ovarian Cancer Early) study, led by a research team from the McGill University Health Centre (MUHC), Canada, and published in a recent issue of The Lancet Oncology. The study could revolutionise the way the disease is diagnosed.

The study also found that women over 50 years who suffer from bloating, high urinary frequency, abdominal or pelvic discomfort are about 10 times more likely to have ovarian cancer than those who do not.

The DOvE project was initiated in May 2008 to assess symptomatic women for ovarian cancer early, when chances of recovery are highest. During the pilot phase of the study, 1,455 women aged 50 years or more were assessed. As a result, cancers were diagnosed earlier, when 73 per cent of women could benefit from complete surgery, leaving no visible disease.

Dr Lucy Gilbert, Director of Gynaecologic Oncology at the MUHC and principal investigator of the DovE study conducted over a period of four years says, “Each year 2,16,000 women worldwide are diagnosed with ovarian cancer, and 70 per cent of them will die unless we act on the information we have without delay. We encourage healthcare professionals around the world to be aware that high grade serous cancer often starts in the fallopian tubes. So the traditional tests — ultrasound scan of the ovaries and the one-off CA125 blood test — are not enough to diagnose high grade serous cancer (HGSC) in time.

“As the killer variety of ovarian cancer is not really cancer of the ovary, we have to rethink the current diagnostic test, or these cancers will be missed,” adds Dr Gilbert, who is also an Associate Professor of Medicine at McGill University.

At Mumbai’s Tata Memorial Cancer Centre, Dr Amita Maheshwari, Associate Professor of Gynaecologic Oncology, agrees that the study is important and certain variant cancers can arise in the fallopian tubes. “There are 28,000 new cases of ovarian cancer every year in the country as against 1.34 lakh new cases of cervical cancer and one lakh new cases of breast cancer,” she says, adding that early detection is important and, sadly, there are no cost effective screening tests for ovarian cancer.

Dr Hemant Tongaonkar, gynaecologic oncologist at Mumbai’s Hinduja Hospital and Research Centre, says that since the early symptoms of ovarian cancer are vague and mimic other conditions, the DoVE study had been taken up to develop a probability tool for detection.

Dr A Nanda Kumar, Director of the National Cancer Registry Programme, Bangalore, says that due to the high mortality, the aetiology of the cancer of the ovary has been the subject of several investigations. Experts agree that ovarian cancer is less common but more deadly. Kumar says this is because we do not have a screening test and most cancers are diagnosed in the advanced stage.

Indian Express

March Is Ovarian Cancer Awareness Month March 2, 2012

Posted by patoconnor in cancer, gynecological cancer, ovarian cancer, tubal cancer, Uncategorized, uterine cancer, vaginal cancer.
Tags: , , , , , , , , ,
add a comment

March Is Ovarian Cancer Awareness Month

AnnA Rushton

March 1, 2012 
Another of the cancers that is linked to excess oestrogen, it is important to be aware of the symptoms and to establish good hormonal balance to reduce your risk of ovarian cancer

Although the majority of the 6,500 women diagnosed with ovarian cancer in the UK each year are menopausal, it is not solely confined to that group as younger women are also at risk.

The good news is that with early detection the survival rate is good with seven out of ten women treated will survive for five or more years.    The bad news is that some of the symptoms are similar to those seen in more common conditions, like irritable bowel syndrome (IBS) so your doctor may find it hard to diagnose.

What Can You Do?

Awareness is key, because to help your doctor diagnose ovarian cancer you need to monitor your body and report any symptoms as soon as you spot them. Also, cervical screening tests (smear tests) will not help to detect ovarian cancer so don’t rely on getting a clear result from that indicating you are clear of ovarian cancer.

Women need to learn to recognise the symptoms and go to see their doctor as soon as possible if they have any of the following consistently over a month and they don’t go away:

Persistent pelvic or abdominal pain

Increased abdominal size/persistent bloating (not the normal blow up around a period that comes and goes)

Difficulty eating or feeling full quickly

Urinary symptoms such as more frequent or urgent need to pee

Those are the most common symptoms, but sometimes there can be other such as:

Changes in bowel habit

Extreme fatigue (feeling very tired)

Unexplained weight loss

If you regularly experience any of these symptoms and they are not normal for you then please don’t hesitate but go and see your doctor.  They may be nothing, but it is important to be checked out.   It will help your doctor if you also keep a note of your symptoms such as when they occur and if related to specific events.  They will also want to know if there is any history of ovarian or breast cancer in your immediate family.

What Treatment Is Available?

First your doctor may suggest a CA125 blood test and, depending upon the results, they may order an internal scan. Alternatively, they may refer you to a specialist gynaecology unit for investigation, or if they do not think ovarian cancer is a likely cause they may ask you to return if your symptoms do not clear over a period of time.

Treatment normally involves chemotherapy and/or surgery – usually a total hysterectomy.  If this is the case then supplemental bio-identical progesterone will help to counter the effects of this sudden surgical menopause.

Reducing Your Risk

Having a healthy hormone balance is essential and monitoring yourself for symptoms of oestrogen dominance, and tackling them would certainly be a good start.  This article by Dame Dr Shirley Bond outlines them here and a diet that reduces other risk factors such as animal fats and refined sugar and replaces them with more plant-based foods, complex carbohydrates and fibre will also be of benefit.

Bio-Health News

Cancer misdiagnosis claim refuted March 2, 2012

Posted by patoconnor in cancer, gynecological cancer, ovarian cancer, tubal cancer, Uncategorized, uterine cancer, vaginal cancer.
Tags: , , , , ,
add a comment

HOSPITAL bosses have disputed claims that three ‘serious’ cases were misdiagnosed by gynaecological departments in Oxford.

The claim was made by an anonymous GP in a survey by a doctors’ magazine.

He told GP journal Pulse he knew of three ‘serious’ cases which had been misdiagnosed by the gynaecological department at the John Radcliffe Hospital – including one of a patient with ovarian cancer.

He said: “We wrote a letter. All we wanted was something back saying ‘let’s look at this’. Instead we got a five-sentence reply saying ‘under Nice guidelines we did nothing negligent’.”

Sir Jonathan Michael, chief executive of the Oxford UniversityHospitals Trust, said: “The trust has robust processes in place to ensure that high standards of clinical care are delivered in our hospitals. If at any time a GP or patient feels that the standard of care received from our trust falls short of their expectations, we urge them to raise these through the appropriate channels.

“It is impossible to comment on such anecdotal comments given anonymously but the trust would be more than happy to address the concerns.”

Oxford Times

Let’s hear it for medical care in Oxford

Ovarian sentinel node: is it feasible? March 1, 2012

Posted by patoconnor in cancer, gynecological cancer, ovarian cancer, tubal cancer, Uncategorized, uterine cancer, vaginal cancer.
Tags: , , ,
add a comment

Ovarian sentinel node: is it feasible?

Nyberg RHKorkola PMäenpää J.

Source

Department of Obstetrics and Gynecology, Tampere University Hospital, Tampere, Finland. reita.nyberg@pshp.fi

Abstract

OBJECTIVE:

To examine whether the intraoperative combined injection technique is feasible in locating the sentinel node(s) of the ovary.

METHODS/MATERIALS:

In 16 patients with high-risk uterine cancer and normal postmenopausal ovaries, technetium isotope and blue dye were injected in the right or left ovary during laparotomy, respectively. During the operation, the pelvic and para-aortic lymphatic areas were searched, and the number, method of detection, and location(s) of the hot and/or bluenode(s) were recorded.

RESULTS:

One to 3 sentinel nodes per patient were identified in all but 1 patient (15 of 16, 94%). The sentinel nodes (n = 30) were all located in the para-aortic area. The sentinel nodes of the left ovary were mainly (9 of 14, 64%) located above the inferior mesenteric artery level, as the most sentinel nodes of the right ovary (15 of 16, 94%) were found below the inferior mesenteric artery level (P = 0.001). There were no contralateral or bilateral sentinel nodes.

CONCLUSIONS:

The combined intraoperative injection technique with radioisotope and blue dye is fast enough to identify the ovarian sentinel node(s). The stained nodes were consistently located on a certain lymphatic area. The sentinel nodeconcept for the early ovarian cancer deserves more attention.

International Journal of Gynecological Cancer

Click on the link for further information on Sentinel Node Biopsy

 

Study: Cryoablation puts a chill on ovarian cancer tumors February 29, 2012

Posted by patoconnor in cancer, gynecological cancer, ovarian cancer, tubal cancer, Uncategorized, uterine cancer, vaginal cancer.
Tags: , , , , ,
add a comment

Study: Cryoablation puts a chill on ovarian cancer tumors

Feb 2012

Cryoablation has been shown to be an effective form of treatment for ovarian cancer, and this “freeze and destroy” technique could offer an alternative to surgery or chemotherapy for patients whose disease is in the late stages and oligometastatic, according to research published in the Journal of Vascular and Interventional Radiology and presented at the 2012 International Symposium on Endovascular Therapy in Miami in January.

Hyun Bang, MD, of the department of radiology at Wayne State University School of Medicine in Detroit, and colleagues performed a study of 21 ovarian cancer patients who underwent ultrasound-guided, percutaneous cryoablation in order to assess complications, recurrences and overall survival. Forty-eight tumors on the soft tissue, liver and lungs were treated during the seven-year study period.

Results showed that the median survival was 56.9 months, though the authors noted an average period of 37.8 months occurred between the diagnosis of metastatic disease to the cryoablation procedure. For comparison, most women whose tumors aren’t successfully removed surgically—approximately 60 percent of cases—survive seven months to 30 months.

Bang and colleagues also calculated that cryoablation delivers results at a lower cost than alternative treatments. Medical costs in the study registered an average of $26,806 per life year saved compared with the current standard of care costing approximately $100,000 per life year saved.

“[Multisite cryoablation] of metastatic epithelial ovarian cancer is a well-tolerated treatment alternative, especially for patients with anesthesia risks, painful lesions or those seeking local control during chemotherapy,” concluded the authors. “Preliminary calculations of high patient survival and cost-effectiveness suggest that cryoablation could effectively and economically augment the palliative care of metastatic disease.”

Because cryoablation is performed using an extremely cold needle inserted into the skin, it causes less pain and offers a faster recovery than surgery, according to the authors.

The research team has published two papers detailing the findings as they relate to kidney and lung cancers, with a third recently submitted on colon cancer. Bang recognized the long-term effectiveness and financial benefits of the treatment in a statement, saying that with enough evidence and proven data, “eventually, people will start listening.”

Ovarian cancer is diagnosed in 22,000 women each year and is the most damaging cancer to the female reproductive system, according to the National Institutes of Health.

Health Imaging

Targeted treatment for ovarian cancer to be studied at University Hospitals February 28, 2012

Posted by patoconnor in cancer, gynecological cancer, ovarian cancer, tubal cancer, Uncategorized, uterine cancer, vaginal cancer.
Tags: , , , , , , , , ,
add a comment

Targeted treatment for ovarian cancer to be studied at University Hospitals

Tuesday, February 28, 2012

CLEVELAND, Ohio — Physicians at University Hospitals Case Medical Center are developing four clinical trials to test a therapy that has been around for several decades, but which only recently has been used to treat ovarian, endometrial (uterine) and select other gynecologic cancers.

The studies, which physicians hope to begin this spring, have been designed for a very specific patient population — no more than a couple dozen women with ovarian or endometrial cancer will be enrolled in each one. The trials will help researchers compare and learn relatively quickly how to use heated intraperitoneal chemotherapy, or HIPEC, as effectively as possible, said Dr. Robert DeBernardo, a gynecologic oncologist at UH and assistant professor at Case Western Reserve University School of Medicine.

The procedure, administered in the operating room right after surgery to remove malignant tumors or tissue, flows a hyperthermic — or heated — sterilized chemotherapy solution through catheters directly into a patient’s abdominal cavity. The heat makes cancer cells “leak” so chemotherapy can enter the cells more effectively.

The effect of chemotherapy delivered directly to the abdomen is more potent than intravenous delivery, which takes longer to reach the intended area. And because the targeted delivery of HIPEC minimizes the rest of the body’s exposure to the treatment, it helps reduce some side effects, such as hair loss.

“Giving chemotherapy in the [operating room] is complicated, but it’s not something that can’t be done,” DeBernardo said. “We need to really show: Is this a beneficial therapy?”

Not only will the studies shed light on how well HIPEC controls when and where the cancer recurs, but they will also focus closely on side effects, costs and the length of hospital stays.

Here are the Phase 1 trials:

• A study involving the use of heated chemotherapy for ovarian cancer that has spread to the chest. What the surgical team has dubbed HITEC (the “T” coming from the word intrathoracic) is performed after minimally invasive lung surgery. “To my knowledge, no one has treated ovarian cancer [that has spread to] the chest like this,” DeBernardo said.

• A study for advanced ovarian-cancer patients whose cancer is in remission following surgery and chemotherapy. The patients will undergo HIPEC to prevent recurrence.

• A study for patients whose cancer recurs; HIPEC will be performed following surgery.

• A study for patients who undergo chemotherapy prior to surgery and HIPEC during the surgery.

Ovarian cancer is especially challenging to treat, as it is often not detected until it has spread. The cancer antigen 125 blood test, which can detect elevated levels of CA-125 — a trait often found in women with ovarian cancer — is not recommended as a screening test in women with an average risk of the disease because elevated levels can signal many other conditions.

Over the past two decades, treatments have evolved and improved, says DeBernardo.

Not only has it become easier to perform aggressive tissue-removing surgery (the primary way to diagnose ovarian cancer), but surgeons have become more specialized in cancer-tissue removal. Women also are able to better tolerate treatment.

“The thing about women with ovarian cancer [is,] we don’t cure very many people with ovarian cancer,” DeBernardo said. “We can control it, we can keep it at bay. But it almost always comes back. That’s where HIPEC comes in. It may improve things.”

The Cleveland Clinic began treating abdominal cancers — appendix, colorectal, gastric, ovarian and peritoneal mesolthelioma (a cancer of the lining of the abdominal cavity) with HIPEC in 2010. UH followed suit last summer, with DeBernardo working with other surgical oncologists and general surgeons to launch the program at UH Seidman Cancer Center.

Buoyed by the results of a national study that appeared in 2006 in the New England Journal of Medicine that showed a higher rate of survival for women with ovarian cancer who were treated with HIPEC versus intravenous chemotherapy, hospitals began to explore the HIPEC option.

“The unfortunate fact is, even though it’s good science, there is still only a minority of women getting offered that treatment,” DeBernardo said. The reasons are varied, and include that not all women have ready access to a hospital with a gynecologic on-

cologist or other skilled staff who are able to integrate HIPEC as part of treatment.

Last August, led by DeBernardo, UH launched a dedicated HIPEC program for gynecological cancers. The surgical team performed its first HIPEC treatment in August 2011. Since then, there have been more than two dozen cases.

Jan Belleville of Hubbard was DeBernardo’s first HIPEC patient.

Other than feeling something — not pain, but something — in her lower abdomen in the summer of 2006, Belleville had no reason to think it was ovarian cancer.

“I had had fibroids and thought that was all it was,” said Belleville, 68. But it wasn’t.

Belleville was diagnosed with Stage 4 ovarian cancer, which by then had spread through her abdominal cavity to her liver. Her first surgery included radiation therapy. Chemotherapy followed.

After being in remission for a year, Belleville’s cancer returned to her liver. She had another operation, followed by more chemotherapy and radiation. The cancer went into remission for six months, then came back. After more chemotherapy, remission again for three months. But the cancer came back again. This time it had spread to her lungs.

After treating Belleville with different types of chemotherapy that proved ineffective, DeBernardo and his colleague, Dr. Jason Robke, decided to do something else.

Last summer, they approached her about having HIPEC/HITEC surgery. She would be their first case.

“I never have doubted that I was being guided in the right direction,” Belleville said.

In late July, she had the first of two HIPEC/HITEC operations, on the left side of her chest. Four weeks later, surgeons operated on the right side. Those surgeries — which were each roughly three hours long, including about 90 minutes for administering the chemotherapy — were the seventh and eighth since she was first diagnosed.

The surgeries stabilized Belleville’s levels of CA-125, the protein in the blood that is found in ovarian cancer cells at a much higher level than in normal cells.

Shortness of breath and lack of energy earlier this month prompted more tests; X-rays detected spots on her lungs, evidence that the cancer had returned there.

Despite the news, Belleville and her husband went ahead with a planned vacation to Florida. Last week, she started intravenous chemotherapy.

“I think it bought me a really nice Thanksgiving, a beautiful holiday over Christmas,” an upbeat Belleville said about the six-month remission that followed her HIPEC/HITEC procedure. “I don’t consider this [recurrence] a setback.”

Cleveland.com

Key discovery in the treatment of ovarian cancer February 26, 2012

Posted by patoconnor in cancer, gynecological cancer, ovarian cancer, tubal cancer, Uncategorized, uterine cancer, vaginal cancer.
Tags: , , , , , ,
add a comment

Key discovery in the treatment of ovarian cancer

Feb 2012

There is a great achievement in the study of ovarian cancer. Researchers have identified a peptide-receptor system, which will help in the understanding the progression and treatment of human ovarian cancer that affects a large population of women worldwide.

For this, researcher conducted this study on immunocompromised mice. They transplanted molecularly engineered humanovarian cancer cells  to have a lower expression of opioidgrowth factor receptor (OGFr). They found that ovarian tumours grew rapidly.

These findings were made by the researchers at The Pennsylvania State  University  College of Medicine, Hershey, Pennsylvania. Their study brings a fresh insight into the pathogenesis and therapy of a lethal cancer that is the fifth most important cause of cancer-related deaths among women in the USA for over 75 years.

The opioid growth factor (OGF)(also-termed [Met5]-enkephalin)-OGFr axis plays a vital role in cancer as it is related to development, and cellular renewal by regulating cell proliferation. This study has also answered the requirement of this peptide-receptor system for the development of carcinogenesis.

The study has also found that Human ovarian cancer call  lines that were genetically engineered to underexpress OGFr developed far more faster in tissue culture than control (empty vector/wildtype) cell lines.

Moreover, adding OGF to cultures of these genetically engineered cells did not respond to the inhibitory peptide and change cell number that showed the loss of OGFr interfered with the function of the OGF-OGFr axis with respect to controlling cell proliferation.

Immunocompromised mice in which ovarian cancer cells were transplanted that showed a reduction in OGFr exhibited tumours much earlier than controls, and these tumours developed more rapidly than controls.

With this knowledge that the pathway for OGF-OGFr regulation of cell proliferation in ovarian cancer is by way of escalating the cyclin-dependent inhibitory kinase proteins p16 and p21, it can be said that reducing the quantity of OGFr results in a rise in the number of cells entering the G1/S phase of the cell cycle.

This process has influence on increasing the progression of tumorigenic events.

These results reflects on the critical nature of OGFr in human ovarian cancer, and that the receptor along with its ligand, OGF, is necessary for deciding the course of these neoplasias.

Dr. Ian S. Zagon and Dr. Patricia J. McLaughlin found that endogenous opioids acts as growth factors, and have been pioneers in translating their findings from the bench to the bedside.

“Ovarian cancers frequently have a methylation of p16 that is associated with an increased progression of ovarian cancer and a loss of OGFr in ovarian tumors,” Dr. Renee N. Donahue a researcher in the Department of Neural and Behavioral Sciences said.

“The diminished expression of OGFr and its repercussions on tumorigenesis, only adds to the concern about the need for information concerning genetic and epigenetic changes that may impact the course of disease and its treatment.

“Our findings also hold potentially ominous overtones for those individuals taking naltrexone for addictive disorders. The dosage used for treatment of addiction blocks opioid receptors continually. The present findings that diminishing the OGF-OGFr axis by depleting the receptor exacerbates tumorigenesis, could place these patients using naltrexone at risk for accelerating disease processes that involve cell proliferation,” Dr. Donahue has been quoted as saying.

Dr. Steven R. Goodman, Editor-in-Chief of ExperimentalBiology and Medicine, opined that this forceful evidence confirmed the absolute requirement for OGFr (and OGF) as a tonically active inhibitory regulatory mechanism in ovarian cancer.

“As a corollary, amplifying the OGF-OGFr pathway is a novel and highly effective biotherapeutic strategy to suppress the progression of these deadly cancers,” Dr Goodman stated.

Experimental Biology and Medicine has published this study.

With inputs from ANI

News

Mother With Ovarian Cancer Fights To Give Back February 26, 2012

Posted by patoconnor in cancer, gynecological cancer, ovarian cancer, tubal cancer, Uncategorized, uterine cancer, vaginal cancer.
Tags: , ,
add a comment

Mother With Ovarian Cancer Fights To Give Back

Feb 2012

MT. LEBANON (KDKA) – A young mother diagnosed with cancer has found a way to give back, by raising $6,000 to donate to a foundation that is helping to keep her alive.

Christina Radzilowicz, 42, of Mt. Lebanon thought that she had done everything right to live a healthy life. She was a runner, ate well and had regular medical check-ups. But none of that prevented her from becoming one of the 70,000 Americans between the ages of 15-and-39 diagnosed each year with cancer.

Three-and-a-half-years ago, her world was turned upside down when she found out she had Ovarian Cancer.

Her son, John, and daughter, Anastasya, were 10 and 6 at the time.

“I can’t let that be the case. Little kids are not projects you can wrap up in a couple of months,” Radzilowicz said.

She decided she needed to stay on this earth for her husband and children.

“I have this obligation that I willingly take to be their mom, and that includes fighting as hard as I can to allow that privilege.”

She found the I’m Too Young To Have Cancer Foundation online, and after listening to their webcasts she found reason for hope.

Radzilowicz has now set a new goal to raise $6,000 and donate it to this foundation. She has raised a quarter of it so far.

She is determined to be at the OMG! Cancer Summit For Young Adults in Las Vegas on March 30, where cancer patients can learn about education, advocacy, research and networking.

Radzilowicz knows that as a wife, mother and woman she has much to share with other young moms about living in the crucible of cancer.

“Yes, cancer may be a part of our lives but we’re going to get busy living,” she said.

MORE INFORMATION

If you’re willing to help Christina – donations can be made through her website, CrowdRise.com/CRad or through Eden’s Market, 99 Alfred Street, Mt. Lebanon, PA 15228 – and you can reach Christina directly atchristina.radzilowicz@gmail.com.

Pitt

 

National Foundation for Cancer Research Funds Novel Approach to Early Detection of Ovarian Cancer February 26, 2012

Posted by patoconnor in cancer, gynecological cancer, ovarian cancer, tubal cancer, Uncategorized, uterine cancer, vaginal cancer.
Tags: , , ,
add a comment

National Foundation for Cancer Research Funds Novel Approach to Early Detection of Ovarian Cancer

Feb 23, 2012

LBUQUERQUE, N.M., Feb 23, 2012 (BUSINESS WIRE) — The National Foundation for Cancer Research has awarded a grant to Dr. Robert C. Bast, Jr. of The University of Texas MD Anderson Cancer Center to work with Senior Scientific LLC, a company owned by Manhattan Scientifics MHTX 0.00% , to apply Senior Scientifics’ technology to the early detection of ovarian cancer.

Senior Scientific has pioneered a novel technology using special magnetic sensors and magnetic nanoparticles for a highly sensitive and very specific approach to cancer detection.

The new grant, entitled “SQUID Imaging for Detection of Early Stage Ovarian Cancer,” will augment Dr. Bast’s ongoing program at The University of Texas MD Anderson Cancer Center with this emerging technology. Dr. Bast is a world leader in the early detection of ovarian cancer and was responsible for the discovery of the most accurate marker for this disease, CA-125.

The principal challenge in this grant is to overcome the problem of early detection of ovarian cancer where only 25% of ovarian cancer patients are currently detected in stage I. When the disease can be detected in Stage 1, 90% of those patients can be cured.

V. Gerald Grafe, president of Senior Scientific, said, “We are delighted with this support from the National Foundation for Cancer Research for our cooperation with Dr. Bast and The University of Texas MD Anderson Cancer Center. The focus of the grant is to combine Senior Scientifics’ highly sensitive technology, developed by our founder, Edward R. Flynn, PhD, with the expertise in cancer-markers developed at The University of Texas MD Anderson Cancer Center by Dr. Bast. Success of the program will allow us to detect ovarian cancer much earlier, leading to life-saving treatment for ovarian cancer patients.”

Dr. Flynn’s research was initially funded by the NIH, with the initial objective to be able to spot cancerous breast tumors years earlier than a mammogram can, with no radiation and high specificity and has now been applied to ovarian cancer. Dr. Flynn’s technology uses microscopic iron oxide nanoparticles, attached to known breast cancer antibodies, which specifically bind to breast cancers. The bound nanoparticles create a magnetic signal that is detected by an ultra sensitive magnetic sensor device developed by Dr. Flynn; this patented technology enables the technician to see the cancer with as few as 100,000 cells. A mammogram typically cannot detect a tumor until at least 100 million cells are present.

The new Ovarian Cancer grant triggers collaboration between Drs. Bast, Flynn & a team led by Richard S. Larson, MD, PhD, Vice Chancellor UNM Health Sciences Center in New Mexico.

About Manhattan Scientifics

Manhattan Scientifics Inc. ( http://www.mhtx.com ) is located in New Mexico, New York and Montreal. It is focused on technology transfer and commercialization of disruptive technologies in the nano medicine space. The company is presently developing commercial medical prosthetics applications for its ultra fine grain metals and plans to commercialize the cancer research work and nano medical applications developed by Senior Scientific LLC, a unit of the Company.

Forward-looking statement

This press release contains forward-looking statements, which are subject to a number of risks, assumptions and uncertainties that could cause the Company’s actual results to differ materially from those projected in such forward-looking statements. Management at Manhattan Scientifics believes that purchase of its shares should be considered to be at the high end of the risk spectrum. Forward-looking statements speak only as of the date made and are not guarantees of future performance. We undertake no obligation to publicly update or revise any forward-looking statements.

SOURCE: Manhattan Scientifics, Inc.

Market

Endometriosis increases ovarian cancer risk February 26, 2012

Posted by patoconnor in cancer, gynecological cancer, ovarian cancer, tubal cancer, uterine cancer, vaginal cancer.
Tags: , ,
add a comment

Endometriosis increases ovarian cancer risk

By Stephen Adams

Thursday February 23 2012

WOMEN who suffer from endometriosis are at more than twice the risk of developing three common forms of ovarian cancer, according to new research.

Celeste Leigh Pearce from the University of Southern CaliforniaLos Angeles, lead author of the study, said the “breakthrough” could lead to screening programmes or risk-reduction surgery for higher-risk women.

She and her team found that endometriosis tripled a woman’s lifetime risk of developing a type called clear cell ovarian cancer, from 1 in 500 to one in 180.

It also more than doubled the risk of two other types, called endometrioid and low-grade serous ovarian cancer, from one in 400 to one in 180.

The US researchers made their conclusions in The Lancet Oncology after looking at data from over 23,000 women, of whom almost 8,000 had invasive ovarian cancer.

Dr Paul Pharoah from Cambridge University said it was “well established” that having endometriosis increased a woman’s lifetime risk of all types of ovarian cancer from about one in 50 to one in 40.

Prof Hani Gabra, director of the Ovarian Cancer Action Research Centre at Imperial College London, described the study as “interesting”.

“However, most women with endometriosis will not go on to develop ovarian cancer,” he added.

“It is important that all women should be aware of the signs and symptoms of ovarian cancer and consult their GP if they are concerned.”

About 10 per cent of women are thought to develop endometriosis, where womb lining tissue develops outside the uterus, although estimates vary. It can cause painful periods, while sex can hurt, and it can reduce fertility too.

– Stephen Adams

In